Abordagem de uma Paciente com Fibrilaçao Atrial e Insuficiência Cardíaca Tratada com Ablaçao do Nó Atrioventricular e Marcapasso Multissítio

Paciente do sexo feminino, com58anos, portadora de cardiomiopatia dilatada, acompanhada desde 1984 por apresentar insuficiência cardíaca e hipertensao arterial. Na evoluçao, apresentou bloqueio de ramo esquerdo e fibrilaçao atrial. No final de 1999, mesmo com a medicaçao adequada e otimizada para insuficiência cardíaca, apresentava-se em grau funcional IV e as internaçoes hospitalares haviam se tornando cada vez mais freqüentes. Em janeiro de 2000, optou-se pela ablaçao do nó atrioventricular e pelo implante de um marcapasso endocárdico bifocal multissítio em ventrículo direito. Desde entao vem evoluindo bem, com menor número de medicamentos e raras internaçoes

Abordagem de uma Paciente com Fibrilaçao Atrial e Insuficiência Cardíaca Tratada com Ablaçao do Nó Atrioventricular e Marcapasso Multissítio

Paciente do sexo feminino, com58anos, portadora de cardiomiopatia dilatada, acompanhada desde 1984 por apresentar insuficiência cardíaca e hipertensao arterial. Na evoluçao, apresentou bloqueio de ramo esquerdo e fibrilaçao atrial. No final de 1999, mesmo com a medicaçao adequada e otimizada para insuficiência cardíaca, apresentava-se em grau funcional IV e as internaçoes hospitalares haviam se tornando cada vez mais freqüentes. Em janeiro de 2000, optou-se pela ablaçao do nó atrioventricular e pelo implante de um marcapasso endocárdico bifocal multissítio em ventrículo direito. Desde entao vem evoluindo bem, com menor número de medicamentos e raras internaçoes

A New Experimental Device for Transapical Access of the Aortic and Mitral Valves as well as the Aorta in its Various Segments

Abstract Objective: To present the results of a new experimental device developed to facilitate the transapical access in endovascular treatment of structural heart diseases. It aims to reduce the risk of bleeding and complications in this type of access and demonstrate the device as a safe, fast and effective alternative. Methods: CorPoint is composed of three parts: introducer, base with coiled spring, and closing capsule. By rotating movements, the spring is introduced into the myocardium and progressively approaches the base to the surface of the heart. Guidewires and catheters are inserted through the hollow central part and, at the end of the procedure, the capsule is screwed over the base, therefore stopping any bleeding. Results: The device was implanted in 15 pigs, weighing 60 kg each, through an anterolateral thoracotomy, while catheters were introduced and guided by fluoroscopy. All animals had minimal bleeding; introducers with diameter up to 22 Fr were used and various catheters and guidewires were easily handled. After finishing the procedure, the closing capsule was attached and no bleeding was observed at the site. Conclusion: This new device has proved effective, fast and secure for the transapical access. This shows great potential for use, especially by ensuring an easier and direct access to the mitral and aortic valves; the shortest distance to be traveled by catheters; access to the ascending and descending aorta; decreased bleeding complications; decreased surgical time; and the possibility of allowing the technique to evolve and become totally percutaneous